Find a Clinical Trial

Trial Description: This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the recommended dose of ASP8374 in combination with cemiplimab for the second portion of the study. The second portion of the study will be to compare the effect of having ASP8374 in combination with cemiplimab prior to surgery. The names of the study

• Conditions: glioblastoma, recurrent glioblastoma
• Phase: I
• Trial ID: NCT04826393
• Protocol ID: 21-054

Trial Description: This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

• Conditions: glioblastoma, recurrent glioblastoma
• Phase: II
• Trial ID: NCT04406272
• Protocol ID: 19-792

Trial Description: This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: - Pembrolizumab - Olaparib - Temozolomide (Temodar)

• Conditions: glioblastoma, recurrent glioblastoma
• Phase: II
• Trial ID: NCT05463848
• Protocol ID: 22-251

Trial Description: This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter

• Conditions: brain tumor, glioblastoma, recurrent glioblastoma, supratentorial glioblastoma
• Phase: II
• Trial ID: NCT04479241
• Protocol ID: 21-223

Trial Description: Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Evaluate safety and tolerability of ibudilast (MN-166) and TMZ combination treatment for 1 cycle (28 days); determine dosage in dose-finding study. Part 2 will evaluate efficacy of fixed-dose MN-166 (ibudilast) and TMZ combination treatment for 6 cycles (~6 months) until disease progression, unacceptable tolerability and/or toxicity or loss of life

• Conditions: gbm, glioblastoma, newly diagnosed glioblastoma, recurrent glioblastoma
• Phase: I/II
• Trial ID: NCT03782415
• Protocol ID: 18-436

Trial Description: This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

• Conditions: glioblastoma, gliosarcoma, mgmt-unmethylated glioblastoma, recurrent glioblastoma
• Phase: I
• Trial ID: NCT03107780
• Protocol ID: 17-453

Trial Description: This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: - Re-irradiation for glioblastoma using a novel Mathematical Model-Adapted Radiation Fractionation Schedule

• Conditions: recurrent glioblastoma
• Phase: Feasibility / Pilot
• Trial ID: NCT03557372
• Protocol ID: 18-105

Trial Description: This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: - Pembrolizumab - Radiation - Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM)

• Conditions: glioblastoma
• Phase: II
• Trial ID: NCT03661723
• Protocol ID: 18-277

Trial Description: The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when added to bevacizumab. Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (nivolumab ) is currently FDA approved in the United States for melanoma (a type of skin cancer), non-small cell lung cancer, renal cell cancer (a type of kidney

• Conditions: glioblastoma
• Phase: II
• Trial ID: NCT03452579
• Protocol ID: 18-298

Trial Description: Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

• Conditions: glioblastoma
• Phase: II/III
• Trial ID: NCT03970447
• Protocol ID: 19-429

Trial Description: This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. "Investigational" means that the intervention is being studied and that research doctors are trying to find more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved the Personalized NeoAntigen Cancer Vaccine for any use in patients

• Conditions: glioblastoma
• Phase: I
• Trial ID: NCT02287428
• Protocol ID: 14-362

Trial Description: This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : - Abemaciclib - Temozolomide (temodar) - Neratinib - CC115 - QBS10072S

• Conditions: glioblastoma
• Phase: II
• Trial ID: NCT02977780
• Protocol ID: 16-443

Trial Description: This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib

• Conditions: glioblastoma
• Phase: II
• Trial ID: NCT02981940
• Protocol ID: 16-383

Trial Description: This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (Nivolumab) is currently FDA approved in the United States for melanoma (a type of skin cancer), non

• Conditions: glioblastoma
• Phase: I
• Trial ID: NCT03636477
• Protocol ID: 18-209

Trial Description: This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. This study will involve participants with recurrent glioblastoma at their first relapse enrolled in two arms including patients who require reoperation and patients not requiring surgery. This research study involves a combination of two drugs: - Pembrolizumab (MK3475) - Abemaciclib (LY2835219)

• Conditions: glioblastoma
• Phase: II
• Trial ID: NCT04118036
• Protocol ID: 19-351

Trial Description: Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).

• Conditions: glioblastoma
• Phase: I/II
• Trial ID: NCT03491683
• Protocol ID: 18-377

Trial Description: This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).

• Conditions: glioblastoma
• Phase: I
• Trial ID: NCT05187624
• Protocol ID: 22-433

Trial Description: This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Cemiplimab-rwlc (Libtayo) is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Libtayo (cemiplimab-rwlc) is currently FDA approved in the United States for metastatic

• Conditions: glioblastoma
• Phase: II
• Trial ID: NCT04006119
• Protocol ID: 19-413

Trial Description: The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly

• Conditions: newly diagnosed glioblastoma
• Phase: III
• Trial ID: NCT03345095
• Protocol ID: 19-564

Trial Description: This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab - Placebo (IV solution with no medicine) - 89Zr-Df-IAB22M2C (optional sub-study)

• Conditions: gbm, glioblastoma, glioblastoma multiforme, grade iv astrocytoma
• Phase: I
• Trial ID: NCT04606316
• Protocol ID: 20-494

Trial Description: This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).

• Conditions: glioblastoma, gliosarcoma
• Phase: II
• Trial ID: NCT01903330
• Protocol ID: 19-222

Trial Description: The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

• Conditions: glioblastoma adult
• Phase: I/II
• Trial ID: NCT04116658
• Protocol ID: 19-608

Trial Description: The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).

• Conditions: glioblastoma multiforme
• Phase: I/II
• Trial ID: NCT03382977
• Protocol ID: 18-156

Trial Description: This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C). - Arm A: evaluating the combination of selinexor with radiation therapy (S-RT) in nGBM participants with uMGMT

• Conditions: glioblastoma multiforme
• Phase: I/II
• Trial ID: NCT04421378
• Protocol ID: 20-283

Trial Description: The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

• Conditions: recurrent glioblastoma
• Phase: I/II
• Trial ID: NCT04417088
• Protocol ID: 20-489

Trial Description: - To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). - To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. - To evaluate the antitumor activity of ERAS-801. - To evaluate the PK profile of ERAS-801.

• Conditions: glioblastoma multiforme
• Phase: I
• Trial ID: NCT05222802
• Protocol ID: 22-201

Trial Description: This protocol has a 2-part design: This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).

• Conditions: glioblastoma adult
• Phase: II
• Trial ID: NCT03522298
• Protocol ID: 18-113

Trial Description: The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy

• Conditions: glioblastoma, glioma
• Phase: Feasibility / Pilot
• Trial ID: NCT03551249
• Protocol ID: 18-484

Trial Description: This research study is studying an immunotherapy as a possible treatment for Glioblastoma.

• Conditions: brain cancer
• Phase: I
• Trial ID: NCT02852655
• Protocol ID: 16-225

Trial Description: This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.

• Conditions: adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma
• Phase: II
• Trial ID: NCT02179086
• Protocol ID: 15-708

Trial Description: The main purpose of this study is to determine whether adding SurVaxM to standard-of-care temozolomide chemotherapy is better than temozolomide treatment alone for patients with newly diagnosed glioblastoma. This study is designed to compare the length of survival in patients with newly diagnosed glioblastoma who receive temozolomide plus SurVaxM to that of patients treated with standard-of-care temozolomide plus placebo. This study aims to discover what effects, both good and bad, this combination of drugs may have on you and to see if the study drug (SurVaxM) can create an immune response in your blood that is directed against your cancer cells. This study also aims to determine whether treatment with SurVaxM plus temozolomide improves the survival of glioblastoma patients like yourself compared to treatment with temozolomide alone.

• Conditions: newly diagnosed glioblastoma
• Phase: II
• Trial ID: NCT05163080
• Protocol ID: 21-397

Trial Description: ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation.

• Conditions: basal ganglia glioma, diffuse midline glioma, glioblastoma, h3 k27m glioma, infratentorial glioma, thalamic glioma
• Phase: I/II
• Trial ID: NCT02525692
• Protocol ID: 15-318

Trial Description: This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

• Conditions: brain neoplasms malignant, leptomeningeal disease (lmd), primary glioblastoma multiforme, recurrent glioblastoma multiforme
• Phase: I
• Trial ID: NCT03423628
• Protocol ID: 18-018

Trial Description: This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

• Conditions: brain and central nervous system tumors
• Phase: Feasibility / Pilot
• Trial ID: NCT03965494
• Protocol ID: 19-829

Trial Description: This phase I trial studies the safety and best dose of anti-LAG-3 (anti-LAG-3 monoclonal antibody BMS-986016) or urelumab alone and in combination with nivolumab in treating patients with glioblastoma that has returned (recurrent). Anti-LAG-3 monoclonal antibody BMS-986016, urelumab, and nivolumab are antibodies (a type of protein) that may stimulate the cells in the immune system to attack tumor cells. It is not yet known whether anti-LAG-3 monoclonal antibody BMS-986016 or urelumab alone or in combination with nivolumab may kill more tumor cells. (The Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)

• Conditions: glioblastoma, gliosarcoma, recurrent brain neoplasm
• Phase: I
• Trial ID: NCT02658981
• Protocol ID: 16-016

Trial Description: This is a study of DSP-0390 in patients with recurrent high grade glioma

• Conditions: glioblastoma multiforme, high grade glioma
• Phase: I
• Trial ID: NCT05023551
• Protocol ID: 22-210

Trial Description: This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways

• Conditions: anaplastic astrocytoma, glioblastoma, malignant glioma
• Phase: II
• Trial ID: NCT03581292
• Protocol ID: 19-702

Trial Description: The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma.

• Conditions: brain and central nervous system tumors
• Phase: I/II
• Trial ID: NCT03150862
• Protocol ID: 17-435

Trial Description: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one pre treatment, during and post standard care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: - Screening for eligibility - Three MRI scans

• Conditions: esophageal cancer, glioblastoma, magnetic resonance imaging, mri, pediatric glioblastoma multiforme, prostate cancer, radiotherapy, vulvar cancer
• Phase: I
• Trial ID: NCT04188535
• Protocol ID: 19-573

Trial Description: This phase I trial studies the side effects of nivolumab and ipilimumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread

• Conditions: glioblastoma, grade iii glioma, malignant glioma, recurrent glioblastoma, recurrent grade iii glioma, recurrent malignant glioma
• Phase: Feasibility / Pilot
• Trial ID: NCT04323046
• Protocol ID: 20-243

Trial Description: The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cancer masses that have metastasized to the brain.

• Conditions: glioblastoma, low grade glioma of brain, metastasis to brain
• Phase: Feasibility / Pilot
• Trial ID: NCT03717142
• Protocol ID: 18-463

by adding indoximod immunotherapy during chemotherapy and/or radiation is a potent approach for breaking immune tolerance to pediatric tumors that will improve outcomes, relative to standard therapy alone. This is an NCI-funded (R01 CA229646, MPI: Johnson and Munn) open-label phase 2 trial using indoximod-based combination chemo-radio-immunotherapy for treatment of patients age 3 to 21 years who have progressive brain cancer (glioblastoma, medulloblastoma, or ependymoma), or newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Statistical analysis will stratify patients based on whether

• Conditions: diffuse intrinsic pontine glioma, ependymoma, glioblastoma, medulloblastoma
• Phase: II
• Trial ID: NCT04049669
• Protocol ID: 22-261

Trial Description: BDTX-1535-101 is a first-in-human, open-label, Phase 1 dose escalation and multiple expansion cohort study designed to evaluate the safety, tolerability, pharmacokinetics (PK), central nervous system (CNS) activity, and preliminary antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations with or without CNS disease, or glioblastoma multiforme (GBM) expressing EGFR alterations. All patients will self administer BDTX-1535 monotherapy in 21-day cycles. One expansion cohort will include patients with newly diagnosed GBM who will self administer BDTX-1535 in combination with temozolomide in 28-day cycles.

• Conditions: advanced lung carcinoma, advanced non-small cell squamous lung cancer, advanced solid tumor, egfr gene mutation, gbm, glioblastoma, metastatic cancer, metastatic lung cancer, metastatic lung non-small cell carcinoma, new diagnosis tumor, non-small cell lung cancer, nsclc, recurrent glioblastoma
• Phase: I
• Trial ID: NCT05256290
• Protocol ID: 22-295

Trial Description: The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors

• Conditions: advanced solid tumors, ccrcc, clear cell renal cell carcinoma, gbm, glioblastoma, glioblastoma multiforme, glioblastoma adult, kidney cancer, rcc, rcc clear cell adenocarcinoma, renal cell carcinoma recurrent, renal cell carcinoma clear cell adenocarcinoma, renal cell carcinoma metastatic, solid carcinoma, solid tumor, solid tumor adult
• Phase: I
• Trial ID: NCT02974738
• Protocol ID: 17-634

Trial Description: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor

• Conditions: anaplastic oligodendroglioma of brain (diagnosis), astrocytoma, brain cancer, brain tumor, ependymoma, ganglioglioma, glioblastoma, glioblastoma multiforme, glioma, malignant astrocytoma, malignant glioma of brain, mixed oligo-astrocytoma, oligodendroglioma, pylocytic/pylomyxoid astrocytoma
• Phase: I
• Trial ID: NCT03152318
• Protocol ID: 16-557

Trial Description: This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

• Conditions: diffuse intrinsic pontine glioma, recurrent anaplastic astrocytoma, recurrent glioblastoma, recurrent malignant glioma, recurrent medulloblastoma
• Phase: I
• Trial ID: NCT03893487
• Protocol ID: 19-372

Trial Description: This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents

• Conditions: glioblastoma, idh1 gene mutation, idh2 gene mutation, low grade glioma, malignant glioma, recurrent glioblastoma, recurrent who grade ii glioma, recurrent who grade iii glioma, who grade ii glioma, who grade iii glioma
• Phase: I
• Trial ID: NCT03749187
• Protocol ID: 19-204

Trial Description: The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors. Dose escalation was guided by a Bayesian logistic regression model with overdose control. Once MTD/ RP2D was declared, glioblastoma patients were enrolled in the phase II part to further assess the preliminary anti-tumor activity of BLZ945 as single agent and in combination with PDR001.

• Conditions: advanced solid tumors
• Phase: I/II
• Trial ID: NCT02829723
• Protocol ID: 20-369

Trial Description: This pilot phase I clinical trial studies how well lapatinib ditosylate before surgery works in treating patients with high-grade glioma that has come back after a period of time during which the tumor could not be detected. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

• Conditions: anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, gliosarcoma, mixed glioma, recurrent adult brain neoplasm, recurrent glioblastoma
• Phase: Feasibility / Pilot
• Trial ID: NCT02101905
• Protocol ID: 14-297

Trial Description: This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas

• Conditions: idh1 mutation, idh2 mutation, recurrent glioblastoma, recurrent who grade ii glioma, recurrent who grade iii glioma
• Phase: I/II
• Trial ID: NCT03914742
• Protocol ID: 19-464